BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15646836)

  • 1. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
    Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
    Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
    Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
    Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
    Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
    Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of three commercially available ELISA kits for the determination of chromogranin A.
    Eeckhout K; Van Cotthem K; Guerti K
    J Immunoassay Immunochem; 2021 Mar; 42(2):95-105. PubMed ID: 33043835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
    Glinicki P; Kapuścińska R; Jeske W
    Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
    Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 9. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
    Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
    Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between three commercial kits for chromogranin A measurements.
    Stridsberg M; Eriksson B; Oberg K; Janson ET
    J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
    Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
    Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
    Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
    Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination.
    Verderio P; Dittadi R; Marubini E; Pizzamiglio S; Gion M; De Apollonia L; Paradiso A;
    Clin Chem Lab Med; 2007; 45(9):1244-50. PubMed ID: 17663633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
    Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
    Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
    Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CisBio ELISA for Chromogranin A Measurement.
    Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
    J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
    Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
    Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.